GLP-3 Peptide 10MG

DESCRIPTION

Retatrutide (LY3437943) is a synthetic peptide investigated as a triagonist of the GLP-1, GIP, and glucagon receptors. It is studied in preclinical and research models for receptor binding, downstream signaling, and comparative receptor activity within the incretin family.

RESEARCH AREAS

• Triagonist receptor activity — studied for simultaneous binding at GLP-1, GIP, and glucagon receptors in cell-based assays.
• Incretin pathway signaling — investigated for cAMP and downstream pathway activation in receptor models.
• Metabolic pathway research — explored in rodent models of altered glucose homeostasis.
• Comparative receptor pharmacology — characterized in published literature alongside other GLP receptor agonists.

WHAT RESEARCHERS LOOK AT

• Mechanism: triple receptor agonism at GLP-1, GIP, and glucagon receptors.
• Receptor binding affinity and selectivity profiles in vitro.
• Pathway activation downstream of receptor binding (cAMP, ERK signaling).
• Comparative profiling against single and dual incretin receptor compounds in preclinical models.

QUICK SPECS

• Form: Lyophilized peptide
• Net per vial: 10 mg
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light

IDENTITY BASICS

• • Type: Triple GLP-1/GIP/glucagon receptor agonist
  • Formula / M.W.: Peptide analog (varies by formulation)

• CAS: 2381089-83-2

SELECTED RESEARCH

• PubChem entry — chemical identity:
  
  https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide
  
• Receptor pharmacology research (NEJM, 2023):
  
  https://pubmed.ncbi.nlm.nih.gov/37323486/
  
• Mechanism of action — triple agonism:
  
  https://pubmed.ncbi.nlm.nih.gov/36006191/
  
• Comparative receptor pharmacology research:
  
  https://pubmed.ncbi.nlm.nih.gov/37323485/
  

⚠️ DISCLAIMER

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.